Tioga Pharmaceuticals to Present Asimadoline Phase 2b Data in Irritable Bowel Syndrome at Digestive Disease Week 2008 Annual Meeting
Posted on: Thursday, 15 May 2008, 09:00 CDT
SAN DIEGO, May 15 /PRNewswire/ -- Tioga Pharmaceuticals announced today that data from a 596 subject Phase 2b study of asimadoline, the company's drug candidate for the treatment of irritable bowel syndrome (IBS), will be featured in a late-breaking oral presentation session at the Digestive Disease Week 2008 Annual Meeting.
Late Breaking Abstract Session Title: Asimadoline in the Treatment of IBS Speaker: Allen Mangel, M.D., Ph.D., Senior Vice President of RTI Health Solutions Date: May 20, 2008 at 3:15p.m. Pacific Time Location: Room 29 at the San Diego Convention Center About Asimadoline
Asimadoline is an orally administered small molecule that is a highly selective kappa opioid receptor agonist. Kappa opioid receptors are found in the digestive tract and are believed to play an important role in control of visceral pain and bowel motility. Asimadoline was originally discovered by Merck KGaA of Darmstadt, Germany. In 2005, Tioga purchased asimadoline from Merck and acquired by assignment all worldwide rights. Asimadoline has been tested in over 1100 subjects and has demonstrated a promising safety profile.
About Tioga
Tioga Pharmaceuticals, Inc. is a pharmaceutical company headquartered in San Diego, CA focused on developing novel treatments for gastrointestinal diseases. Tioga is currently planning Phase 3 development of asimadoline for the treatment of D-IBS and A-IBS and a Phase 2b trial of asimadoline for the treatment of functional dyspepsia. Both disorders represent a large unmet medical need and a substantial market opportunity. For more information, please visit http://www.tiogapharma.com/.
Contact: David Urso, Chief Business Officer and General Counsel Phone: 858-964-5021 Email: urso@tiogapharma.com Media: Cory Tromblee, Porter Novelli Life Sciences Phone: 617-897-8294 Email: ctromblee@pnlifesciences.com
Tioga Pharmaceuticals, Inc.
CONTACT: David Urso, Chief Business Officer and General Counsel of TiogaPharmaceuticals, Inc., +1-858-964-5021, urso@tiogapharma.com; or media, CoryTromblee of Porter Novelli Life Sciences, +1-617-897-8294,ctromblee@pnlifesciences.com, for Tioga Pharmaceuticals, Inc.
Web site: http://www.tiogapharma.com/
Source: PRNewswire
Related Articles
- CTIA, West Wireless Health Institute, Qualcomm, and CommNexus San Diego Present: San Diego - The Nation's Hub for Wireless Healthcare
- VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
- Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
- Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Program of APD791 for the Treatment of Arterial Thrombosis
- Arena Pharmaceuticals Initiates Phase 2 Clinical Trial of APD125 for the Treatment of Insomnia
- EPIX Pharmaceuticals Initiates Phase 2a Clinical Trial in Patients With Mild Alzheimer's Disease
- Alaska Airlines Announces New Nonstop Service Between San Diego and San Francisco
- Optimer Pharmaceuticals Initiates Phase 3 Clinical Trials of OPT-99 for the Treatment of Gastroenteritis
- Vitae Pharmaceuticals Initiates Phase II Clinical Trials for Two Novel Compounds for Psoriasis and Cancer Conditions
- Paratek Pharmaceuticals Announces Phase I Trial of PTK 0796, a New Broad-Spectrum Antibiotic
 |
 |
User Comments (0)
RSS Feeds